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Small cell lung cancer (SCLC) is one of the most aggres-sive and lethal cancers in humans. It constitutes approxi-
mately 15 to 25% of all cases of primary lung cancers.1 Initial
response rates of 70 to 90% for both limited and extensive
stages of SCLC may be achieved using standard combination
cytotoxic chemotherapy agents. The 5-year survival for lim-
ited-state SCLC is 15 to 25%, but patients with extensive-
stage SCLC rarely survive 5 years. Even among patients who
achieve a complete response, there is a high rate of relapse.2
Until recently, there has been no well-established treat-
ment available for patients with recurrent SCLC.3 Topotecan
is a camptothecin analogue that stabilizes the covalent adduct
between topoisomerase I and DNA. In S-phase cells, these
topo I-DNA adducts are converted into double-strand breaks
that seem to be responsible for cytotoxicity.4 Several phase
II5–8 trials as well as a phase III trial3 have demonstrated
antitumor efficacy, manageable toxicities, and acceptable
safety profile of topotecan in both chemo-naive and previ-
ously treated patients with SCLC. Patients in the topotecan
group derived significant palliative benefits in general symp-
toms (e.g., anorexia, fatigue, interference with daily activi-
ties, and pulmonary symptoms) over CAV chemotherapy in a
randomized trial.3 Although topotecan is currently approved
for second-line therapy in SCLC at a starting dose of 1.5
mg/m2 by a daily 30-minute intravenous infusion for 5
consecutive days of a 21-day cycle, advanced age, extensive
pretreatment, prior platinum therapy, prior radiotherapy, and
renal impairment are potential risk factors for increased
myelosuppression during topotecan therapy. Several studies
suggest that the 1.0- and 1.25-mg/m2 doses of topotecan may
be appropriate for patients with such high-risk factors.9–11
Paclitaxel is a chemotherapeutic agent that promotes
the assembly and stabilization of microtubules. Such binding
causes cells to form abundant arrays of disorganized and
dysfunctional microtubules, leading to apoptosis. Although
there is documented single-agent activity of paclitaxel in
phase II studies among chemo-naive patients with SCLC with
extensive disease,12,13 response duration is short, which sug-
gests that paclitaxel is not sufficient as a single agent. It is
also widely accepted that combinations of cytotoxic drugs
produce higher response rates and survival rates in patients
with SCLC compared with single-agent therapy. The combi-
nation of topotecan and paclitaxel is rational as they have
non-overlapping mechanisms of action and are both active
agents in SCLC, as discussed previously. Moreover, there is
demonstrable in vitro synergy of this combination in SCLC
cell lines,14,15 although there are insufficient data on se-
quence-specific synergy.
Phase II trials of the combination of topotecan and
paclitaxel that have been reported used a 5-day topotecan
schedule as first-line treatment in patients with extensive
SCLC.16–19 A randomized phase II study evaluating four
treatment combinations17 showed that paclitaxel (230 mg/m2
on day 1) plus topotecan (1 mg/m2 on days 1-5) produced
excessive toxicity, with toxic deaths occurring in 25% of
patients. Objective response rate was 54% with a median
survival of 13.8 months. The toxicities were ameliorated in
the treatment arm using an attenuated paclitaxel dose of 175
mg/m2, with treatment-related death occurring in 3% of
patients. Objective response rate in this arm was 69% with a
median survival of 9.9 months and 1-year survival of 40%,
similar to standard etoposide plus cisplatin chemotherapy.
Another phase II trial in patients with chemo-naive
extensive SCLC used topotecan 1 mg/m2 (first three patients
received 1.25 mg/m2) daily for 5 days and paclitaxel (135
mg/m2) on day 5 via a 24-hour infusion every 4 weeks.16
Despite prophylactic G-CSF administration, this combination
was associated with a high incidence of myelosuppression
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and febrile neutropenia, with 31 of 32 patients experiencing
grade 4 neutropenia, albeit brief and not associated with
life-threatening febrile neutropenia. Thirty episodes of febrile
neutropenia occurred in 22 patients. Overall objective re-
sponse rate was 69%. The median survival was 54 weeks.
The 1-, 2-, and 3-year survival rates were 50%, 10%, and 3%,
respectively.
Accordingly, because of the activity observed as front-
line therapy, we initiated a phase II trial to investigate the
efficacy of the combination of topotecan and paclitaxel in
relapsed or refractory small-cell lung cancer. Recognizing
that second-line treatment is not curative and that these
patients have a limited survival, we elected to use a 3-day
regimen of topotecan and paclitaxel in anticipation that it
would be more convenient and less toxic than the 5-day
topotecan regimen and would prove to be more effective
because of the addition of a second active agent.
PATIENTS AND METHODS
Patient Eligibility/Exclusion Criteria
Eligibility included patients aged 18 years with East-
ern Cooperative Oncology Group performance score (PS) of
0-2 who had relapsed or refractory disease after one prior
treatment regimen for a histologically or cytologically con-
firmed diagnosis of small-cell lung cancer. Patients with
tumors exhibiting mixed histology were not eligible. Patients
were required to have measurable disease, defined as at least
one lesion whose longest diameter could be accurately mea-
sured as 2 cm. Adequate hematologic (absolute neutrophil
count [ANC] 1500/l; platelet count 100,000/l; hemo-
globin 9.0 g/dl), renal (serum creatinine 1.5 times the
upper normal limits), and hepatic functions (serum total
bilirubin 1.5 times the upper normal limits or direct biliru-
bin less than or equal to the upper normal limits) were
required for enrollment.
Patients were excluded from the study if they had a
concurrent malignancy or history of another malignancy
(except skin cancer or localized prostate cancer) within the
preceding 3 years, uncontrolled symptoms from central ner-
vous system metastasis (i.e., patients with treated central
nervous system metastasis who were clinically stable were
eligible), uncontrolled infection or precarious cardiovascular
reserve (e.g., unstable angina pectoris, myocardial infarction,
or class III/IV heart failure within the preceding 3 months).
Patients were also excluded if they had undergone major
surgery or preceding systemic chemotherapy within 21 days
or radiation therapy within 14 days before treatment. Because
the study involved investigational agents whose genotoxic,
mutagenic, and teratogenic effects on the developing fetus
and newborn were unknown, men or women of child-bearing
potential who were unwilling to use adequate contraception
were excluded, as were pregnant or nursing women. All
patients signed an informed consent that was approved by the
respective institutional review boards.
Treatment Schema
Patients were categorized into two groups depending on
their prior response to treatment. Arm A included patients
progressing after 3 months of first-line therapy, and arm B
included patients progressing 3 months after completing
one previous treatment regimen.
We aimed to maintain paclitaxel dose intensity, as
sequential Phase II studies had suggested a possible dose-
response effect with paclitaxel when administered with other
cytotoxic agents.20 Topotecan dose reductions, however, are
not necessarily associated with decreased efficacy.21 To be
cautious, the toxicity profile was evaluated for the first six
patients enrolled into the study at four selected institutions
(six patients may be from arm A or arm B or any combina-
tion) treated with a topotecan dose of 1.0 mg/m2 days 1-3,
after which paclitaxel 200 mg/m2 was administered on day 3,
with a cycle length of 28 days. The doses were not escalated
on subsequent cycles.
After demonstrating good tolerance at that dose, the
topotecan dose was escalated to 1.25 mg/m2 daily for 3 days,
which was our target dose and was 75% of the dose of
topotecan usually used in phase II trials. Treatment remained
at this dose if grade 3 infection, grade 4 neutropenia that
was either prolonged (5 days) or associated with fever, or
grade 4 thrombocytopenia occurred in one or none of the
second cohort of the six patients. If two or more of the six
patients experienced the aforementioned toxicities, the dose
of 1.0 mg/m2 would be used throughout the rest of the study.
Dose modification guidelines for non-hematologic grade 3 or
4 toxicities (other than neuropathy) required a 25% dose
reduction of either or both drugs. If treatment delay for
adequate recovery of blood counts or serum creatinine re-
quired 4 weeks, patient would be removed from the study
and go to event monitoring.
G-CSF/GM-CSF was not to be used with the initial
cycle of chemotherapy because of the expense associated
with G-CSF support and the shorter schedule of topotecan
(3-day rather than standard 5-day regimen tested in phase II
trials). If the patient experienced excessive myelosuppres-
sion, the dosage reductions were followed per guidelines. Use
of G-CSF/GM-CSF for subsequent cycles was at the discre-
tion of the attending physician.
Patients who developed metastases in the central ner-
vous system as the only site of disease progression were not
required to leave the study but could receive therapeutic
whole-brain radiation therapy and thereafter continue on the
protocol. Imaging studies were scheduled to be obtained after
every other 28-day cycle. Response Evaluation Criteria in
Solid Tumors criteria were used in the evaluation of treatment
response.22 All responses were confirmed for at least 4 weeks.
Patients who achieved a complete response received a max-
imum of six cycles of the combination chemotherapy on
study. The Common Toxicity Criteria version 2.0 was used
for adverse event monitoring and reporting.
Study Design
This study used a two-staged study design based on
Simon23 for each patient group (arm A: patients progressing
3 months after previous treatment; arm B: patients pro-
gressing3 months after previous treatment). This study was
designed to detect an increase in response rate from 15% in
each arm with a 5% type I error rate and power of 80% for
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detecting a true response probability of 30%. For each study
arm, 19 patients were enrolled into the study and evaluated.
This included the six patients already evaluated for toxicity at
the same dose level. If three or fewer responses were ob-
served on a given arm, accrual to the study arm would be
stopped for lack of efficacy. Otherwise, patient accrual would
continue into stage 2 analysis, into which an additional 36
patients (total of 55 patients per arm) were enrolled. To be
considered an active treatment in an arm, confirmed re-
sponses must have been observed in at least 13 of the first 55
evaluable patients on that arm.
RESULTS
Patient Demographics
Between July 1998 and March 2002, 84 patients were
accrued to the study. Two of these patients refused to partic-
ipate before receiving any treatment and four others were
deemed ineligible by pathology review, leaving 78 patients
evaluable for the primary end point of response. Six of these
patients (three on each arm) were treated at a lower dose of
topotecan before escalating the dosage for the remaining
patients. Table 1 lists the demographic data of the 78 evalu-
able patients. Most patients (87%) had PS 1. Baseline
characteristics were comparable except for the male to female
ratio inversion between the two groups. Except for seven pa-
tients in arm B for whom information about prior therapy was
missing (i.e., specific drugs used, administration of thoracic
radiation and/or prophylactic cranial irradiation), all patients
received a platinum-containing regimen for first-line therapy.
We did not collect data on response status to prior therapy.
Toxicities
The first three patients entered into each arm received a
lower dose of topotecan (1.0 mg/m2) as an initial evaluation
of toxicities that may be encountered. This dose was well
tolerated. Nonhematologic toxicities were grade 1 and 2
(alopecia, myalgia, arthralgia, fatigue, nausea, and sensory
neuropathy were the most common), except for grade 3
sensory neuropathy that occurred in one patient. Although
five of the first six patients had grade 3 to 4 neutropenia
occurring throughout most cycles of treatment, the prespeci-
fied conditions for subsequent dose reduction to 1.0 mg/m2
(see Treatment Schema) did not occur and thus the topotecan
dose was maintained at the target dose of 1.25 mg/m2 for the
remaining patients. The median number of treatment cycles
for arms A and B were three and four, respectively. The
toxicity analysis includes all evaluable patients (n 78). The
most frequently encountered grade 3 and 4 toxicities were
neutropenia (92%), leukopenia (77%), thrombocytopenia
(29%), fatigue (22%), and dyspnea (10%). GCSF was given
on 42 cycles (15% of cycles) to 22 patients (28% of patients).
Neutropenia (grades 3 and 4) was comparable in the cycles
with and without GCSF. Cycles during which GCSF was
administered had similar rates of grade 3 and 4 overall
hematologic toxicities, although grade 3 or 4 thrombocyto-
penia was increased in the cycles in which GCSF was
administered. Two deaths from neutropenic infections oc-
curred in arm B. Grade 3 or 4 nonhematologic toxicities
occurred in 51% of patients (Table 2). Of the patients, 38%
required dose reductions (35% in arm A, 40% in arm B), and
19% required treatment delay (17% in arm A, 20% in arm B)
because of toxicities.
Clinical Activity
Arm A was closed to further accrual after interim
analysis of results from 23 patients revealed insufficient
activity of the combination in chemo-refractory patients with
SCLC to meet stage I decision criteria for protocol continu-
TABLE 1. Patient Demographics
Characteristics
Arm A ( n  23) Arm B ( n  55) Total ( n 78)
n % n % n %
Age 62 (38–79) 62 (42–82) 62 (38–82)
(median and range)
Gender
Male 15 65.2 22 40.0 37 47.4
Female 8 34.8 33 60.0 41 52.6
Race
White 23 100.0 53 96.4 76 97.4
Black 0 0.0 1 1.8 1 1.3
Native American 0 0.0 1 1.8 1 1.3
Performance scorea
0-1 20 87.0 42 87.5 62 87.3
2 3 13.0 6 12.5 9 12.7
Presence of stable brain metastases at study entrya 3 13.0 7 14.6 10 14.1
Previous chemotherapy 23 100.0 55 100.0 78 100.0
Previous chemotherapy  TRT1 5 21.7 33 68.8 38 53.5
Previous chemotherapy  TRT  PCIa 2 8.7 19 39.6 21 29.6
an  71 (arm A: n  23; arm B: n  48). TRT, thoracic radiation; PCI, prophylactic cranial irradiation.
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ation (Table 3). Among the first six patients who received
topotecan at the 1.0-mg/m2 dose level, there was only one
response seen in arm B. Seven patients had documented brain
metastases after initiation of study treatment. Only three of
these seven patients remained on the protocol after complet-
ing whole-brain radiation, receiving one, two, and four addi-
tional cycles, respectively, for stable extracranial disease.
These patients were coded as having stable disease. The four
remaining patients had progressive clinical deterioration or
developed brain metastases after being off study treatment
because of extracranial disease progression. The study was
not powered to examine gender differences in responses;
Fisher’s P values for both arms when examining response
versus gender were 0.50.
The overall objective response rate of patients with
refractory disease was 8.7%; median time to progression was
2.8 months (95% CI, 2.0–3.7). The overall objective response
rate of patients in “sensitive” relapse was 27.3%; median time
to progression was 3.7 months (2.2–5.3). Survival outcomes
for both groups are shown in Table 4. Figure 1 is a graphic
representation of the comparative Kaplan-Meier survival
curves for both treatment groups.
DISCUSSION
Phase II trials of the combination of topotecan and
paclitaxel as first-line treatment in patients with extensive
SCLC have been reported.16–19 These trials used a 5-day
topotecan schedule at doses of 1.0 to 1.25 mg/m2 in combi-
nation with paclitaxel 175 to 230 mg/m2 or 135mg/m2 infu-
sion on day 1 or 5, respectively, every 3 or 4 weeks. These
combinations were thought to demonstrate efficacy similar to
standard platinum-based therapy. However, treatment-related
deaths and myelosuppression were frequent despite G-CSF
support, particularly with the higher paclitaxel dose. Even
with single-agent topotecan, hematologic toxicities occurred
frequently, with Grade 3 or 4 neutropenia encountered in up
to 75% of courses.
Patients with recurrent disease typically have cumula-
tive toxicities from prior chemotherapy exposure, which may
predispose these patients to myelosuppression. An alternate
dosing regimen for topotecan in combination with paclitaxel
is thus rational in the hopes of ameliorating myelosuppression
associated with topotecan treatment, particularly in a pre-
treated population. However, despite the modification from a
standard 5-day to a 3-day topotecan schedule, the combina-
tion of topotecan with paclitaxel in our study was still
associated with a high rate of myelosuppression.3,5
West et al.24 reported the results of a dose-escalation
phase IB trial in patients with chemo-naive SCLC treated
with intravenous paclitaxel 135 to 175 mg/m2 over 1 hour on
day 1, followed by intravenous topotecan 1.25 to 1.5 mg/m2
over 30 minutes on days 1 to 3 of a 21-day course. Dose-
limiting neutropenia was seen in three of five patients treated
with topotecan 1.5 mg/m2 and paclitaxel 175 mg/m2. Topo-
tecan 1.5 mg/m2 with paclitaxel 135 mg/m2 was thus deter-
mined to be the maximal tolerated dose. In contrast to our
studies and the aforementioned phase II combination trials,
only 24% (4 of 17) of patients in West et al.’s phase IB trial
experienced grade 3 or 4 neutropenia, most of whom received
paclitaxel 175 mg/m2 and topotecan 1.5 mg/m2. Routine
G-CSF support was not used. The overall response of 53%
(nine patients with partial response of 17 evaluable patients)
was similar to response rates observed among previously
untreated patients using the 5-day topotecan regimen in
combination with other agents. These toxicity and efficacy
results should be interpreted with caution because of differ-
ences in patient characteristics (previously untreated patients
versus patients with relapsed disease) and the limited number
of patients enrolled. Nevertheless, the results seemed to
TABLE 2. Grade 3 Toxicities Most Frequently Encountered (All Cycles of Treatment)
Toxicity
Arm A Arm B Total
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Hematologic
Leukopenia 48 17 45 36 46 31
Neutropenia 13 74 15 80 14 78
Thrombocytopenia 22 4 22 9 21 8
Non-hematologic
Fatigue 17 0 20 3 19 3
Dyspnea 4 0 11 1 9 1
Myalgia 9 0 3 0 5 0
Nausea 9 0 3 0 5 0
Sensory neuropathy 9 0 4 0 6 0
Data are expressed as percentages.






n (%) 95% CI n (%) 95% CI
Complete response 1 (4.3) (0.1,22.0) 4 (7.3) (2.0,17.6)
Partial response 1 (4.3) (0.1,22.0) 11 (20.0) (10.4,33.0)
Total 2 (8.7) (1.1,28.0) 15 (27.3) (16.1,41.0)
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indicate that a 3-day topotecan regimen in combination with
lower-dose paclitaxel is feasible and still has clinically rele-
vant activity despite lower dose intensity by preserving rel-
ative dose density with a 21-day versus a 28-day cycle
interval.
Response to second-line therapy is influenced by the
progression-free interval from cessation of initial therapy.5–6
Patients who relapse within 3 months are considered to have
refractory disease and typically have response rates to sec-
ond-line therapy that are inferior to patients considered to
have sensitive disease, generally defined as those who expe-
rience relapse more than 3 months after therapy.5 Our results
were not clearly inferior to those reported in a phase II trial
testing the combination of paclitaxel (175 mg/m2 by a 3-hour
intravenous infusion) and carboplatin (AUC  7) among 35
patients with SCLC who experienced relapse within 3 months
of first-line treatment with cyclophosphamide doxorubicin
and etoposide.25 Although the published objective response
rate was 73.5% (95% CI 59% to 88%) and median survival
was 31 weeks, the high response rate can be attributed to the
difference in patient selection: the patients in the latter trial
were not previously exposed to any platinum agent, whereas
nearly all of our patients had a platinum-based regimen for
first-line therapy. Moreover, the 1-year survival rates are
similar between the two studies, highlighting the dismal
prognosis for this group of patients. Nonetheless, the combi-
nation we tested was not effective in patients with SCLC with
chemo-refractory disease. Our study outcomes were similar
to those of single-agent topotecan when comparing the his-
torical objective response rate of 2 to 11% and median overall
survival time of 16 to 21 weeks among chemo-refractory
patients.4–7,10
Among patients considered to have sensitive relapsed
disease, the antitumor activity of the regimen in our study
performed variably compared with other agents. The objec-
tive response rate among our patients in sensitive relapse
seems to be better than the historical objective response rate
of 16.7% obtained with single-agent gemcitabine26 among
patients considered to have chemo-sensitive relapsed SCLC.
Combinations of vinorelbine with gemcitabine or doxorubi-
cin induced partial responses of 25 to 26.5% among patients
in published phase II studies,27,28 similar to our findings.
Likewise, the historical objective response rate of 21.7%
among this group of patients treated with CAV in a phase III
trial is comparable to our findings.2 Phase II trials of irino-
tecan-based combinations with or without cisplatin did, how-
ever, produce apparently better objective response rates of
37.5 to 78% among patients previously exposed to platinum,
TABLE 4. Survival Outcomes by Treatment Arm
Survival
Arm A (refractory) (n  23) Arm B (sensitive) (n  55)
Point estimate 95% CI Point estimate 95% CI
Overall Survival
1 year 13.0% (4.5%, 37.5%) 30.9% (20.8%, 45.9%)
2 year 4.3% (0.6%, 29.6%) 7.3% (2.8%, 18.7%)
Median survival (months) 5.7 (4.3, 7.5) 6.9 (5.8, 8.4)
Progression-free survival
6 months 13.0% (4.5%, 37.5%) 22.7% (13.8%, 37.3%)
12 months 4.3% (0.6%, 29.6%) 3.8% (1.0%, 14.7%)
FIGURE 1. Comparison of Kaplan-Meier survival curves by treatment arm.
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but not better survival rates.29–32 Finally, the modest activity
seen in our study among patients with SCLC in sensitive
relapse was not evidently better than results seen from early
studies with single-agent topotecan in several trials in terms
of objective response rate, which ranged from 14 to 38%, and
median survival, which ranged from 25 to 36 weeks. This
may be explained in part by treatment delays because of
toxicity.
In conclusion, the dose schedule used in this study was
associated with high rates of myelosuppression and modest
clinical efficacy. Although this regimen is not recommended
for further study, the combination of paclitaxel and topotecan
is active, and the value of alternative dosing and scheduling
schemes, such as weekly topotecan or paclitaxel, should be
further investigated. Given the refractory state of relapsed
SCLC to conventional chemotherapy, trials are needed to
explore treatment with novel therapeutic agents.
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